Severe drug-induced liver injury in patients under treatment with antipsychotic drugs: Data from the AMSP study

References

• Aithal GP. 2015. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int. 35:1801–1808.
   PubMed Web of Science ®Google Scholar
• Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, et al. 2011. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 89:806–815.
   PubMed Web of Science ®Google Scholar
• Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. 2013. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of iceland. Gastroenterology. 144:1419.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Olsson R. 2005. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 42:481–489.
   PubMed Web of Science ®Google Scholar
• Bressolle F, Bres J, Blanchin MD, Gomeni R. 1984. Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. J Pharm Sci. 73:1128–1136.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, Watkins PB, Navarro V, Barnhart H, et al. 2015. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 148:1340–1352. e7.
   PubMed Web of Science ®Google Scholar
• Chang A, Krygier DS, Chatur N, Yoshida EM. 2009. Clozapine-induced fatal fulminant hepatic failure: a case report. Can J Gastroenterol. 23:376–378.
   PubMed Web of Science ®Google Scholar
• Clopper C, Pearson E. 1934. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 26:404–413.
   Web of Science ®Google Scholar
• Conley RR, Meltzer HY. 2000. Adverse events related to olanzapine. J Clin Psychiatry 61Suppl 8:26–29; discussion 30.
   Google Scholar
• Crooks J, O'Malley K, Stevenson IH. 1976. Pharmacokinetics in the elderly. Clin Pharmacokinet. 1:280–296.
   PubMedGoogle Scholar
• Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, Goldstein DB, John S, Nelson MR, et al.; International SAE Consortium. 2009. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 41:816–819.
   PubMed Web of Science ®Google Scholar
• Das A, Guarda LA, Allen LG. 2017. Liver injury associated with quetiapine: an illustrative case report. J Clin Psychopharmacol. 37:623–625.
   PubMed Web of Science ®Google Scholar
• De Abajo FJ, Montero D, Madurga M, Rodríguez LAG. 2004. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 58:71–80.
   PubMed Web of Science ®Google Scholar
• De Hert M, Schreurs V, Vancampfort D, Van Winkel R. 2009. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 8:15–22.
   PubMed Web of Science ®Google Scholar
• Derby LE, Gutthann SP, Jick H, Dean AD. 1993. Liver disorders in patients receiving chlorpromazine or isoniazid. Pharmacotherapy. 13:353–358.
   PubMed Web of Science ®Google Scholar
• Dominguez-Jimenez JL, Puente-Gutierrez JJ, Pelado-Garcia EM, Cuesta-Cubillas D, Garcia-Moreno AM. 2012. Liver toxicity due to olanzapine. Rev Esp Enferm Dig. 104:617–618.
   PubMed Web of Science ®Google Scholar
• Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Sarganas G, Kreutz R, Garbe E. 2015. Drug-induced liver injury: Results from the hospital-based berlin case-control surveillance study. Br J Clin Pharmacol. 79:988–999.
   PubMed Web of Science ®Google Scholar
• Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora J-F, Aubriot-Delmas B, Glikman J, Januel D. 2002. Hepatic tolerance of atypical antipsychotic drugs. Encephale. 28:542–551.
   PubMed Web of Science ®Google Scholar
• Dusi N, Comacchio C, Lasalvia A. 2019. Late-onset cholestatic liver injury during combination treatment with chlorpromazine and olanzapine: a case report. J Clin Psychopharmacol. 39:175–176.
   PubMed Web of Science ®Google Scholar
• Eftekhari A, Azarmi Y, Parvizpur A, Eghbal MA. 2016. Involvement of oxidative stress and mitochondrial/lysosomal cross-talk in olanzapine cytotoxicity in freshly isolated rat hepatocytes. Xenobiotica. 46:369–378.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. 2019. Clinical practice guidelines: drug-induced liver injury. J Hepatol. 70:1222–1261.
   PubMed Web of Science ®Google Scholar
• Evans DA. 1986. Ethnic differences in reactions to drugs and xenobiotics acetylation. Prog Clin Biol Res. 214:209–242.
   PubMedGoogle Scholar
• Friedrich M-E, Akimova E, Huf W, Konstantinidis A, Papageorgiou K, Winkler D, Toto S, Greil W, Grohmann R, Kasper S, et al. 2016. Drug-induced liver injury during antidepressant treatment: results of AMSP, a drug surveillance program. IJNPPY. 19:pyv126.
   Google Scholar
• Friis H, Andreasen PB. 1992. Drug-induced hepatic injury: an analysis of 1100 cases reported to the danish committee on adverse drug reactions between 1978 and 1987. J Intern Med. 232:133–138.
   PubMed Web of Science ®Google Scholar
• Grohmann R, Engel RR, Moller HJ, Ruther E, van der Velden JW, Stubner S. 2014. Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study. Eur Arch Psychiatry Clin Neurosci. 264:131–141.
   PubMed Web of Science ®Google Scholar
• Grohmann R, Engel RR, Ruther E, Hippius H. 2004. The AMSP drug safety program: methods and global results. Pharmacopsychiatry. 37:S4–S11.
   PubMed Web of Science ®Google Scholar
• Himmerich H, Kaufmann C, Schuld A, Pollmacher T. 2005. Elevation of liver enzyme levels during psychopharmacological treatment is associated with weight gain. J Psychiatr Res. 39:35–42.
   PubMed Web of Science ®Google Scholar
• Hurwitz N, Wade OL. 1969. Intensive hospital monitoring of adverse reactions to drugs. Br Med J. 1:531–536.
   PubMed Web of Science ®Google Scholar
• Ishak KG, Irey NS. 1972. Hepatic injury associated with the phenothiazines. clinicopathologic and follow-up study of 36 patients. Arch Pathol. 93:283–304.
   PubMedGoogle Scholar
• Jones JK, Van de Carr SW, Zimmerman H, Leroy A. 1983. Hepatotoxicity associated with phenothiazines. Psychopharmacol Bull. 19:24–27.
   PubMed Web of Science ®Google Scholar
• Kaplowitz N. 2004. Drug-induced liver injury. Clin Infect Dis. 38 Suppl 2:S44–S48.
   PubMed Web of Science ®Google Scholar
• Kaplowitz N. 2005. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 4:489–499.
   PubMed Web of Science ®Google Scholar
• Kaplowitz N, Aw TY, Simon FR, Stolz A. 1986. Drug-induced hepatotoxicity. Ann Intern Med. 104:826–839.
   PubMed Web of Science ®Google Scholar
• Katarey D, Verma S. 2016. Drug-induced liver injury. Clin Med (Lond). 16:S104–S109.
   PubMedGoogle Scholar
• Kohler GI, Bode-Boger SM, Busse R, Hoopmann M, Welte T, Boger RH. 2000. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther. 38:504–513.
   PubMed Web of Science ®Google Scholar
• Kolpe M, Ravasia S. 2003. Effect of olanzapine on the liver transaminases. Can J Psychiatry. 48:210.
   PubMed Web of Science ®Google Scholar
• Lally J, Al Kalbani H, Krivoy A, Murphy KC, Gaughran F, MacCabe JH. 2018. Hepatitis, interstitial nephritis, and pancreatitis in association with clozapine treatment: a systematic review of case series and reports. J Clin Psychopharmacol. 38:520–527.
   PubMed Web of Science ®Google Scholar
• Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. 2008. Relationship between daily dose or oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 47:2003–2009.
   PubMed Web of Science ®Google Scholar
• Lin CH, Liu CM, Huang WL. 2012. Quetiapine-induced hepatocellular damage. Psychosomatics. 53:601–602.
   PubMed Web of Science ®Google Scholar
• Lucena MI, Andrade RJ, Kaplowitz N, García-Cortes M, Fernández MC, Romero-Gomez M, Bruguera M, Hallal H, Robles-Diaz M, Rodriguez-González JF, et al; Spanish Group for the Study of Drug-Induced Liver Disease. 2009. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 49:2001–2009.
   PubMed Web of Science ®Google Scholar
• Lv Q, Yi Z. 2018. Antipsychotic drugs and liver injury. Shanghai Arch Psychiatry. 30:47–51.
   PubMedGoogle Scholar
• MacIntyre AC, Cutler DJ. 1988. The potential role of lysosomes in tissue distribution of weak bases. Biopharm Drug Dispos. 9:513–526.
   PubMed Web of Science ®Google Scholar
• Marwick KF, Taylor M, Walker SW. 2012. Antipsychotics and abnormal liver function tests: systematic review. Clin Neuropharmacol. 35:244–253.
   PubMed Web of Science ®Google Scholar
• Meunier L, Larrey D. 2019. Drug-induced liver injury: biomarkers, requirements, candidates, and validation. Front Pharmacol. 10:1482.
   PubMed Web of Science ®Google Scholar
• Milic S, Lulic D, Stimac D. 2014. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol. 20:9330–9337.
   PubMed Web of Science ®Google Scholar
• Naharci MI, Karadurmus N, Demir O, Bozoglu E, Ak M, Doruk H. 2011. Fatal hepatotoxicity in an elderly patient receiving low-dose quetiapine. Am J Psychiatry. 168:212–213.
   PubMed Web of Science ®Google Scholar
• Navarro VJ, Senior JR. 2006. Drug-related hepatotoxicity. N Engl J Med. 354:731–739.
   PubMed Web of Science ®Google Scholar
• Navarro V. Hepatic adverse event nomenclature document (online). [accessed 2009 Feb 5]. http://www.fda.gov/cder/livertox/presentations2005/Vic_Navarro.ppt
   Google Scholar
• Ozcanli T, Erdogan A, Ozdemir S, Onen B, Ozmen M, Doksat K, Sonsuz A. 2006. Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity. Prog Neuropsychopharmacol Biol Psychiatry. 30:1163–1166.
   PubMed Web of Science ®Google Scholar
• Pham TV, Lu S, Kaplowitz N. 1997. Acetaminophen hepatotoxicity. In: Taylor MB, editor. Gastrointestinal emergencies. 2nd ed. Baltimore (MD): Williams & Wilkins; p. 371–388.
   Google Scholar
• Quevedo BC, Salgado MM. 2011. Neuroleptic-induced toxic hepatitis. Actas Esp Psiquiatr. 39:79–80.
   PubMed Web of Science ®Google Scholar
• Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. 1990. Comorbidity of mental disorders with alcohol and other drug abuse. results from the epidemiologic catchment area (ECA) study. JAMA. 264:2511–2518.
   PubMed Web of Science ®Google Scholar
• Seidl LG, Thornton GF, Cluff LE. 1965. Epidemiological studies of adverse drug reactions. Am J Public Health Nations Health. 55:1170–1175.
   PubMed Web of Science ®Google Scholar
• Sherlock S. 1989. Classifying chronic hepatitis. Lancet. 2:1168–1170.
   Web of Science ®Google Scholar
• Shpaner A, Li W, Ankoma-Sey V, Botero RC. 2008. Drug-induced liver injury: hepatotoxicity of quetiapine revisited. Eur J Gastroenterol Hepatol. 20:1106–1109.
   PubMed Web of Science ®Google Scholar
• Slim M, Medina-Caliz I, Gonzalez-Jimenez A, Cabello MR, Mayoral-Cleries F, Lucena MI, Andrade RJ. 2016. Hepatic safety of atypical antipsychotics: current evidence and future directions. Drug Saf. 39:925–943.
   PubMed Web of Science ®Google Scholar
• Solian® Product Information. 2006. Solian® Tablets and Solution [accessed 2020 Jan 7]. http://www.mentalmeds.org/prescription_meds/Solian.pdf
   Google Scholar
• Urichuk L, Prior TI, Dursun S, Baker G. 2008. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 9:410–418.
   PubMed Web of Science ®Google Scholar
• Vatsalya V, Pandey A, Schwandt ML, Cave MC, Barve SS, Ramchandani VA, McClain CJ. 2016. Safety assessment of liver injury with quetiapine fumarate XR management in very heavy drinking alcohol-dependent patients. Clin Drug Investig. 36:935–944.
   PubMed Web of Science ®Google Scholar
• Vollset SE. 1993. Confidence intervals for a binomial proportion. Stat Med. 12:809–824.
   PubMed Web of Science ®Google Scholar
• Wójcikowski J, Daniel WA. 2000. Distribution interactions between perazine and antidepressant drugs. In vivo studies. Pol J Pharmacol. 52:449–457.
   PubMedGoogle Scholar
• Wu Chou AI, Lu ML, Shen WW. 2014. Hepatotoxicity induced by clozapine: a case report and review of literature. Neuropsychiatr Dis Treat. 10:1585–1587.
   PubMed Web of Science ®Google Scholar